Learn More
BACKGROUND High flow nasal cannulae (HFNC) are small, thin, tapered binasal tubes that deliver oxygen or blended oxygen/air at gas flows of more than 1 L/min. HFNC are increasingly being used as a form of non-invasive respiratory support for preterm infants. OBJECTIVES To compare the safety and efficacy of HFNC with other forms of non-invasive respiratory(More)
BACKGROUND Docosahexaenoic acid (DHA) has been associated with downregulation of inflammatory responses. OBJECTIVE To report the effect of DHA supplementation on long-term atopic and respiratory outcomes in preterm infants. METHODS This study is a multicenter, randomized controlled trial comparing the outcomes for preterm infants <33 weeks' gestation(More)
BACKGROUND Some neonatologists state that at the delivery of extremely premature infants they rely on "how the baby looks" when deciding whether to initiate resuscitation. Previous studies have reported poor correlation between early clinical signs and prognosis. OBJECTIVE To determine if neonatologists can accurately predict survival to discharge of(More)
BACKGROUND High-flow nasal cannulae (HFNC) are gaining in popularity as a form of non-invasive respiratory support for preterm infants in neonatal intensive care units around the world. They are proposed as an alternative to nasal continuous positive airway pressure (NCPAP) in a variety of clinical situations, including post-extubation support, primary(More)
The use of high-flow nasal cannula (HF) therapy as respiratory support for preterm infants is rapidly increasing, due to its perceived ease of use and other potential benefits over the standard 'non-invasive' respiratory support, continuous positive airway pressure (CPAP). The evidence from randomized trials suggests that HF is an alternative to CPAP for(More)
BACKGROUND Treatment with nasal high-flow therapy has efficacy similar to that of nasal continuous positive airway pressure (CPAP) when used as postextubation support in neonates. The efficacy of high-flow therapy as the primary means of respiratory support for preterm infants with respiratory distress has not been proved. METHODS In this international,(More)
INTRODUCTION High flow (HF) therapy is an increasingly popular mode of non-invasive respiratory support for preterm infants. While there is now evidence to support the use of HF to reduce extubation failure, there have been no appropriately designed and powered studies to assess the use of HF as primary respiratory support soon after birth. Our hypothesis(More)
AIM Non-tertiary centres (NTCs) in Australia and New Zealand are increasingly providing non-invasive respiratory support, including high-flow nasal cannulae (HFNC) and nasal continuous positive airway pressure (nCPAP), to newborn infants. We aimed to determine the proportion of NTCs in these countries treating newborn infants with HFNC and nCPAP, and how(More)
AIM This study aims to assess nursing perceptions of high-flow nasal cannulae (HFNC) in comparison with nasal continuous positive airway pressure (NCPAP) as post-extubation respiratory support for very preterm infants. METHODS A standardised questionnaire form was distributed in person to nursing staff in The Royal Women's Hospital neonatal unit, where(More)
BACKGROUND Noise exposure in the neonatal intensive care unit is believed to be a risk factor for hearing loss in preterm neonates. Continuous positive airway pressure (CPAP) devices exceed recommended noise levels. High flow nasal cannulae (HFNC) are an increasingly popular alternative to CPAP for treating preterm infants, but there are no in vivo studies(More)